Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F Schatzberg

Showing results (1-10 of 256) with videos related to

Pageof 26
Sort By:
The American Journal of Psychiatry|May 12, 2021
Can Target Engagement Studies Miss Their Targets and Mislead Drug Development?Alan F Schatzberg
The American Journal of Psychiatry|March 4, 2014
A word to the wise about ketamineAlan F Schatzberg
The Journal of Clinical Psychiatry|March 30, 2004
Pharmacologic treatments of major depression: are two mechanisms really better than one?Alan F Schatzberg
The American Journal of Psychiatry|October 2, 2019
More Thoughts on Intranasal Esketamine: Response to Drevets et alAlan F Schatzberg
The American Journal of Psychiatry|December 1, 2022
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major DepressionAlan F Schatzberg
The American Journal of Psychiatry|May 22, 2019
A Word to the Wise About Intranasal EsketamineAlan F Schatzberg
The American Journal of Psychiatry|July 1, 2022
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?Alan F Schatzberg
The American Journal of Psychiatry|December 20, 2015
Opioids in Psychiatric Disorders: Back to the Future?Alan F Schatzberg
The Psychiatric Clinics of North America|August 25, 2015
Development of New Psychopharmacological Agents for Depression and AnxietyAlan F Schatzberg
Human Psychopharmacology|October 31, 2002
Pharmacological principles of antidepressant efficacyAlan F Schatzberg
Pageof 26

Showing results (1-10 of 256) with videos related to

Sort By:
Pageof 26
The American Journal of Psychiatry|May 12, 2021
Can Target Engagement Studies Miss Their Targets and Mislead Drug Development?Alan F Schatzberg
The American Journal of Psychiatry|March 4, 2014
A word to the wise about ketamineAlan F Schatzberg
The Journal of Clinical Psychiatry|March 30, 2004
Pharmacologic treatments of major depression: are two mechanisms really better than one?Alan F Schatzberg
The American Journal of Psychiatry|October 2, 2019
More Thoughts on Intranasal Esketamine: Response to Drevets et alAlan F Schatzberg
The American Journal of Psychiatry|December 1, 2022
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major DepressionAlan F Schatzberg
The American Journal of Psychiatry|May 22, 2019
A Word to the Wise About Intranasal EsketamineAlan F Schatzberg
The American Journal of Psychiatry|July 1, 2022
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?Alan F Schatzberg
The American Journal of Psychiatry|December 20, 2015
Opioids in Psychiatric Disorders: Back to the Future?Alan F Schatzberg
The Psychiatric Clinics of North America|August 25, 2015
Development of New Psychopharmacological Agents for Depression and AnxietyAlan F Schatzberg
Human Psychopharmacology|October 31, 2002
Pharmacological principles of antidepressant efficacyAlan F Schatzberg
Pageof 26